Anika to Issue Second-Quarter 2019 Financial Results and Business Highlights on Wednesday, July 24

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2019 financial results after the close of the market on Wednesday, July 24, 2019 and hold its investor conference call on the same day, Wednesday, July 24, 2019, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "Investor Relations" section of Anika's website, www.anikatherapeutics.com. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika's orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®,which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190710005042/en/

For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung, 781-457-9000 Chief Financial Officer For Media Inquiries: W2O Group Sonal Vasudev, 917-523-1418 [e-mail]